|
Title
|
|
|
|
Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Antibiotics and cystic fibrosis transmembrane conductance regulator (CFTR) modulators play a pivotal role in cystic fibrosis (CF) treatment, but both have limitations. Antibiotics are linked to antibiotic resistance and disruption of the airway microbiome, while CFTR modulators are not widely accessible, and structural lung damage and pathogen overgrowth still occur. Complementary strategies that can beneficially modulate the airway microbiome in a preventive way are highly needed. This could be mediated via oral probiotics, which have shown some improvement of lung function and reduction of airway infections and exacerbations, as a cost-effective approach. However, recent data suggest that specific and locally administered probiotics in the respiratory tract might be a more targeted approach to prevent pathogen outgrowth in the lower airways. This review aims to summarize the current knowledge on the CF airway microbiome and possibilities of microbiome treatments to prevent bacterial and/or viral infections and position them in the context of current CF therapies. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Cell reports medicine
| |
|
Publication
|
|
|
|
2024
| |
|
DOI
|
|
|
|
10.1016/J.XCRM.2023.101371
| |
|
Volume/pages
|
|
|
|
5
:1
(2024)
, p. 1-14
| |
|
Article Reference
|
|
|
|
101371
| |
|
ISI
|
|
|
|
001167816800001
| |
|
Pubmed ID
|
|
|
|
38232705
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|